

原著

Satoko Oda, Kenji Ashida, Makiko Uchiyama, Shohei Sakamoto, Nao Hasuzawa, Ayako Nagayama, Lixiang Wang, Hiromi Nagata, Ryuichi Sakamoto, Junji kishimoto, Koji Todaka, Yoshihiro Ogawa, Yoichi Nakanishi, and Masatoshi Nomura

An Open-label phase I / II a Clinical Trial of 11 β -HSD1 Inhibitor for Cushing's

Syndrome and Autonomous Cortisol Secretion

The Journal of Clinical Endocrinology & Metabilism, 2021, Vol.106, No.10, e3865-e3880

Nao Hasuzawa, Sawako Moriyama, Lixiang Wang, Ayako Nagayama, Kenji Ashida, Yoshinori Moriyama, Masatoshi Nomura

Quinacrine is not a vital fluorescent probe for vesicular ATP storage

Purinergic Signalling, 2021, Vol.17, No.4, 725-735

Lixiang Wang, Xin Li, Yuki Hanada, Nao Hasuzawa, Yoshinori Moriyama, Masatoshi Nomura, Ken Yamamoto.

Dynamin-related protein 1 deficiency accelerates lipopolysaccharide-induced acute liver injury and inflammation in mice.

Communication Biology, 2021, Vol.4, No.1, 894

Hitomi Nakayama, Yasushi Yamada, Kentaro Yamada, Shimpei Iwata, Nobuhiko Wada, Yuji Tajiri, Masatoshi Nomura

Distinct Relevance of Nightly Sleep Duration to Metabolic, Anthropometric, and Lifestyle Factors in Patients with Type 2 Diabetes

Internal Medicine, 2021, Vol.60, No5, 681-688

Moeko Sakamoto, Yuka Goto, Ayako Nagayama, Mamiko Yano, Shuichi Sato, Yuji Tajiri, Masatoshi Nomura

Two-year administration of sodium-glucose co-transporter 2 inhibitor brought about marked reduction of body fat independent of skeletal muscle amount or glycemic improvement in Japanese patients with type 2 diabetes.

Diabetol Int 13(1) :117-123, 2021